Effectiveness of 2 Weeks Administration of Potassium Competitive Acid Blocker vs Proton Pump Inhibitor Therapy in Patients with H. pylori Induced Gastritis in Pakistan: PCAB vs PPI Therapy in Patients with H. pylori Induced Gastritis

Muhammad Areeb Iqbal; Khalid Mahmud Khan; Ayesha Shabbir; Usman Tahir; Sadia Ahmad; Nadia Rasheed; Samrah Khalid

doi:10.54393/pjhs.v7i1.3533

Authors

Muhammad Areeb Iqbal Department of Medicine, Jinnah Hospital, Lahore, Pakistan
Khalid Mahmud Khan Royal College of Physicians, United Kingdom
Ayesha Shabbir Department of Medicine, Jinnah Hospital, Lahore, Pakistan
Usman Tahir Department of Medicine, Jinnah Hospital, Lahore, Pakistan
Sadia Ahmad Department of Medicine, Jinnah Hospital, Lahore, Pakistan
Nadia Rasheed Department of Medicine, Jinnah Hospital, Lahore, Pakistan
Samrah Khalid Department of Medicine, Jinnah Hospital, Lahore, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v7i1.3533

Keywords:

Helicobacter pylori, Potassium Competitive Acid Blocker, Proton Pump Inhibitor Therapy, 2 Weeks Administration

Abstract

Helicobacter pylori cause major gastric and associated gastrointestinal complications, including gastritis and gastric malignancy. Latest evidence hints at the decline in the effectiveness of therapies having conventional proton pump inhibitors (PPI). Potassium competitive acid blockers (PCAB) have emerged as a potential option owing to longer and faster duration of action. However, limited data are available locally comparing PPI to PCAB-based therapies. Objectives: To compare and contrast the efficacy of two weeks of PCAB vs. PPI-based bismuth-containing quadruple therapy for H. pylori eradication. Methods: The quasi-experimental study conducted at the Department of Medicine, Jinnah Hospital, Lahore, recruited a total of 120 patients (60 in each group), aged 18-70 years, with confirmed H. pylori gastritis. Group A received Vonoprozan (PCAB) while Group B received Esomeprazole (PPI). Results: 86.67% of the patients achieved effectiveness in group A as compared to only 68.33% in group B, with a duration of symptoms of 8 weeks, almost similar in each group. The difference in effectiveness was statistically significant. (p=0.016). Conclusions: Vonoprazan (PCAB) based quadruple therapy is more effective at treating H. pylori-induced gastritis than Esomeprazole (PPI) containing therapies.

References

Rugge M, Savarino E, Sbaraglia M, Bricca L, Malfertheiner P. Gastritis: The Clinico-Pathological Spectrum. Digestive and Liver Disease. 2021 Oct; 53(10): 1237-46. doi: 10.1016/j.dld.2021.03.007. DOI: https://doi.org/10.1016/j.dld.2021.03.007

Chiu YT, Lee FJ, Kuo CY, Lin YC, Liang KS, Tseng LW et al. Seven‐Day Vonoprazan‐Based Triple Therapy as First‐Line Helicobacter Pylori Treatment in Comparison with Extended Sequential Therapy. Journal of Gastroenterology and Hepatology Open. 2023 Feb; 7(2): 105-9. doi: 10.1002/jgh3.12858. DOI: https://doi.org/10.1002/jgh3.12858

Kanu JE and Soldera J. Treatment of Helicobacter Pylori with Potassium Competitive Acid Blockers: A Systematic Review and Meta-Analysis. World Journal of Gastroenterology. 2024 Mar; 30(9): 1213. doi: 10.3748/wjg.v30.i9.1213. DOI: https://doi.org/10.3748/wjg.v30.i9.1213

Zhang M, Pang M, Zhang M. Efficacy and Safety of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors as Helicobacter pylori Eradication Therapy: A Meta-Analysis of Randomized Clinical Trials. Clinics. 2022 Aug; 77: 100058. doi: 10.1016/j.clinsp.2022.100058. DOI: https://doi.org/10.1016/j.clinsp.2022.100058

Huh KY, Chung H, Kim YK, Lee S, Bhatia S, Takanami Y et al. Evaluation of Safety and Pharmacokinetics of Bismuth‐Containing Quadruple Therapy with Either Vonoprazan or Lansoprazole for Helicobacter pylori Eradication. British Journal of Clinical Pharmacology. 2022 Jan; 88(1): 138-44. doi: 10.1111/bcp.14934. DOI: https://doi.org/10.1111/bcp.14934

Simadibrata DM, Syam AF, Lee YY. A Comparison of Efficacy and Safety of Potassium‐Competitive Acid Blocker and Proton Pump Inhibitor in Gastric Acid‐Related Diseases: A Systematic Review and Meta‐Analysis. Journal of Gastroenterology and Hepatology. 2022 Dec; 37(12): 2217-28. doi: 10.1111/jgh.16017. DOI: https://doi.org/10.1111/jgh.16017

Lin Y, Xu H, Yun J, Yu X, Shi Y, Zhang D. The Efficacy of Vonoprazan Combined with Different Dose Amoxicillin on Eradication of Helicobacter Pylori: An Open, Multicenter, Randomized Clinical Study. Annals of Translational Medicine. 2022 Sep; 10(18): 987. doi: 10.21037/atm-22-4133. DOI: https://doi.org/10.21037/atm-22-4133

Kim JS, Ko W, Chung JW, Kim TH. Efficacy of Tegoprazan‐Based Bismuth Quadruple Therapy Compared with Bismuth Quadruple Therapy for Helicobacter pylori Infection: A Randomized, Double‐Blind, Active‐Controlled Study. Helicobacter. 2023 Jun; 28(3): E12977. doi: 10.1111/hel.12977. DOI: https://doi.org/10.1111/hel.12977

Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, A Novel Potassium-Competitive Acid Blocker, as A Component of First-Line and Second-Line Triple Therapy for Helicobacter pylori Eradication: A Phase III, Randomized, Double-Blind Study. Gut. 2016 Sep; 65(9): 1439-46. doi: 10.1136/gutjnl-2015-311304. DOI: https://doi.org/10.1136/gutjnl-2015-311304

Maruyama M, Tanaka N, Kubota D, Miyajima M, Kimura T, Tokutake K et al. Vonoprazan‐Based Regimen Is More Useful Than PPI‐Based One as a First‐Line Helicobacter pylori Eradication: A Randomized Controlled Trial. Canadian Journal of Gastroenterology and Hepatology. 2017; 2017(1): 4385161. doi: 10.1155/2017/4385161. DOI: https://doi.org/10.1155/2017/4385161

Sostek MB, Chen Y, Andersson T. Effect of Timing of Dosing in Relation to Food Intake on the Pharmacokinetics of Esomeprazole. British Journal of Clinical Pharmacology. 2007 Sep; 64(3): 386-90. doi: 10.1111/j.1365-2125.2007.02889.x. DOI: https://doi.org/10.1111/j.1365-2125.2007.02889.x

Matsumoto H, Shiotani A, Katsumata R, Fujita M, Nakato R, Murao T et al. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance. Digestive Diseases and Sciences. 2016 Nov; 61(11): 3215-20. doi: 0.1007/s10620-016-4305-0. DOI: https://doi.org/10.1007/s10620-016-4305-0

Yamada S, Kawakami T, Nakatsugawa Y, Suzuki T, Fujii H, Tomatsuri N et al. Usefulness of Vonoprazan, A Potassium Ion-Competitive Acid Blocker, for Primary Eradication of Helicobacter pylori. World Journal of Gastrointestinal Pharmacology and Therapeutics. 2016 Nov; 7(4): 550. doi: 10.4292/wjgpt.v7.i4.550. DOI: https://doi.org/10.4292/wjgpt.v7.i4.550

Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology. 2022 Sep; 163(3): 608-19. doi: 10.1053/j.gastro.2022.05.055. DOI: https://doi.org/10.1053/j.gastro.2022.05.055

Alboraie M, Elhossary W, Aly OA, Abbas B, Abdelsalam L, Ghaith D et al. Egyptian Recommendations for Management of Helicobacter pylori Infection: 2018 Report. Arab Journal of Gastroenterology. 2019 Sep; 20(3): 175-9. doi: 10.1016/j.ajg.2019.09.001. DOI: https://doi.org/10.1016/j.ajg.2019.09.001

Yan TL, Wang JH, He XJ, Zhu YB, Lu LJ, Wang YJ et al. Ten-Day Vonoprazan-Amoxicillin Dual Therapy vs Standard 14-Day Bismuth-Based Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Multicenter Randomized Clinical Trial. Official Journal of the American College of Gastroenterology. 2024 Apr; 119(4): 655-61. doi: 10.14309/ajg.0000000000002592. DOI: https://doi.org/10.14309/ajg.0000000000002592

Du RC, Hu YX, Ouyang Y, Ling LX, Xu JY, Sa R et al. Vonoprazan and Amoxicillin Dual Therapy as the First‐Line Treatment of Helicobacter pylori Infection: A Systematic Review and Meta‐Analysis. Helicobacter. 2024 Jan; 29(1): e13039. doi: 10.1111/hel.13039. DOI: https://doi.org/10.1111/hel.13039

Zhou BG, Jiang X, Ding YB, She Q, Li YY. Vonoprazan‐Amoxicillin Dual Therapy Versus Bismuth‐Containing Quadruple Therapy for Helicobacter Pylori Eradication: A Systematic Review and Meta‐Analysis. Helicobacter. 2024 Jan; 29(1): e13040. doi: 10.1111/hel.13040. DOI: https://doi.org/10.1111/hel.13040

Kong Q, Mirza IA, Zhang X, Song X, Li X, Zhang Q et al. Fourteen‐Day Tegoprazan–Amoxicillin Dual Therapy as the First‐Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial. Helicobacter. 2024 May; 29(3): e13098. doi: 10.1111/hel.13098. DOI: https://doi.org/10.1111/hel.13098

Tungtrongchitr N, Bongkotvirawan P, Ratana-Amornpin S, Siramolpiwat S, Eiamsitrakoon T, Gamnarai P et al. Fourteen-Day Vonoprazan-Based Bismuth Quadruple Therapy for H. pylori Eradication in an Area with High Clarithromycin and Levofloxacin Resistance: A Prospective Randomized Study (VQ-HP Trial). Scientific Reports. 2024 Apr; 14(1): 8986. doi: 10.1038/s41598-024-59621-3. DOI: https://doi.org/10.1038/s41598-024-59621-3